MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-08-2025
Surmodics Cash Conversion Cycle 2011-2026 | SRDX
Annual Cash Conversion Cycle Surmodics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 169 | 179 | 158 | 129 | 114 | 78 | 54.8 | 48.4 | 63 | 76.5 | 57.9 | 72.4 | 127 | 117 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 179 | 48.4 | 103 |
Quarterly Cash Conversion Cycle Surmodics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158 | 187 | 194 | - | 171 | 191 | 158 | - | 166 | 202 | 205 | - | 85.5 | 157 | 150 | - | 121 | 136 | 152 | 66.7 | 117 | 117 | 104 | 48.7 | 99.2 | 92.3 | 75.6 | 48.7 | 69.1 | 76.5 | 79.6 | 45.4 | 72.1 | 36.8 | 34.4 | 34.5 | 31.4 | 31.8 | 35.9 | 39.3 | 42.9 | 32.9 | 29.5 | 28.3 | 29.7 | 33.1 | 34.3 | 35.1 | 34.9 | 32.5 | 31.2 | 32.4 | 32.4 | 32.4 | 30.1 | 28.8 | 30.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 205 | 28.3 | 81.9 |
Cash Conversion Cycle of other stocks in the Diagnostics research industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
224 | $ 8.9 | 0.39 % | $ 593 M |  USA |
 |
Castle Biosciences
CSTL
|
45.9 | $ 26.04 | 0.81 % | $ 723 M | USA |
 |
Aspira Women's Health
AWH
|
-38.7 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
134 | $ 68.33 | 2.99 % | $ 26.7 B | USA |
 |
Guardant Health
GH
|
79.6 | $ 87.63 | 0.52 % | $ 11 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 154.73 | 1.82 % | $ 7.67 B | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 17.59 | 1.56 % | $ 937 M | USA |
 |
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 168.86 | 2.41 % | $ 29 B | USA |
 |
Exact Sciences Corporation
EXAS
|
42.5 | $ 103.89 | 0.04 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
42.4 | $ 15.62 | 4.45 % | $ 472 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
41.7 | $ 16.88 | -2.37 % | $ 2.19 B | USA |
 |
ICON Public Limited Company
ICLR
|
62 | $ 100.35 | 2.81 % | $ 8.28 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
275 | $ 2.9 | 2.11 % | $ 94.1 K | USA |
 |
Danaher Corporation
DHR
|
77.5 | $ 195.77 | 2.29 % | $ 140 B | USA |
 |
NeoGenomics
NEO
|
82.4 | $ 8.36 | 1.46 % | $ 1.07 B | USA |
 |
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
185 | $ 1.4 | 2.95 % | $ 420 M | USA |
 |
Illumina
ILMN
|
142 | $ 121.89 | 2.18 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 198.82 | -0.06 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
111 | $ 113.9 | 1.85 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
225 | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
207 | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
Neogen Corporation
NEOG
|
150 | $ 9.32 | 2.25 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
97.3 | $ 78.96 | 0.59 % | $ 5.33 B | USA |
 |
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
299 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 452.34 | -0.29 % | $ 13 B | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 219.76 | 1.76 % | $ 25.1 B |  Schweiz |
 |
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | USA |
 |
Twist Bioscience Corporation
TWST
|
83.6 | $ 46.61 | 3.55 % | $ 2.79 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 18.05 | 3.71 % | $ 404 M | USA |
 |
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
81.5 | $ 199.84 | 1.09 % | $ 19.7 B | USA |